TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21288539
Drug: nC‐AT (non
Approvals — FDA: no, EMA: no, PMDA: no
Description: nC‐AT (non computer-assisted treatment, conventional language stimulation procedures)
Study: 19853105
Drug: Alternative topical
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative topical hemostatic agents
Study: 17368254
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (without oxytocin infusion)
Study: 15222727
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of ciprofloxacin 750 mg (supplied by Dr. August Wolff GmbH and Co., Germany)
Study: 10026839
Drug: SR 49059
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 49059 1 mg
Study: 10026839
Drug: SR 49059
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 49059 10 mg
Study: 10026839
Drug: SR 49059
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 49059 100 mg
Study: 10026839
Drug: SR 49059
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 49059 300 mg
Study: 10026839
Drug: SR 49059
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 49059 600 mg
Study: 15889952
Drug: Intramuscular haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular haloperidol decanoate
Study: 2106534
Drug: Haloperidol in
Normalized name: Haloperidol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol in combination with carbamazepine
Study: 2106534
Drug: Haloperidol in
Normalized name: Haloperidol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol in combination with lithium carbonate
Study: 28361441
Drug: Telephone-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based cognitive behavioral therapy (T-CBT)
Study: 29077152
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight Sodium Hyaluronate (3%) plus saline solution (NaCl 0.9%) twice a day for 30 days
Study: 29077152
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution twice a day for 30 days
Study: 13678770
Drug: Alendronate 2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 2.5-10 mg per day for 2 years
Study: 13678770
Drug: Alendronate 20
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate 20 mg per day for 2 years
Study: 10515039
Drug: Alisate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisate (300 mg, 1 tablet twice a day for 4-6 weeks)
Study: 10515039
Drug: Conventional antirheumatic
Normalized name: ANTIRHEUMATICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antirheumatic therapy
Study: 26189154
Drug: Combination intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination intervention strategy (CIS)
Study: 25835622
Drug: Intermediate Dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate Dose (ID) - 76.8Gy < BED 10 < 100.8 Gy (e.g., >64 Gy/32 fr and <74 Gy/37 fr)
Study: 25835622
Drug: Standard Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Dose (SD) - 72Gy ≤ BED 10 ≤ 76.8 Gy (e.g., 60‐64 Gy/30‐32 fractions)
Study: 25835622
Drug: Intermediate Dose
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate Dose (ID)
Study: 19536605
Drug: Continued pharmacological
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued pharmacological treatment
Study: 16776781
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prescription and voucher after 3 months)
Study: 11579891
Drug: Sulfadoxine-pyrimethamine (SP)
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine (SP) - dosage: pyrimethamine 1.25 mg/kg and sulfadoxine 25 mg/kg, single dose
Study: 11579891
Drug: Proguanil (PG)
DrugBank: Proguanil (DB01131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proguanil (PG) plus Dapsone (DS) - dosage: PG 10 mg/kg and DS 2.5 mg/kg each day for 3 days
Study: 9443139
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy in addition to coaching in breathing from partners during labor
Study: 8098885
Drug: Nootropic piracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nootropic piracetam (daily dosage 1.2 g)
Study: 3755554
Drug: Brufen 200
Normalized name: Brufen 200 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brufen 200 mg tablets
Study: 3755554
Drug: Inza 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inza 200 mg and 400 mg tablets
Study: 31805385
Drug: Preoperative fascia
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative fascia iliaca block (35-40 mL ropivacaine 0.35%)
Study: 19369319
Drug: haloperidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (1 to 4 mg/day)
Study: 19369319
Drug: amisulpride (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: amisulpride (200 to 800 mg/day)
Study: 19369319
Drug: olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: olanzapine (5 to 20 mg/day)
Study: 19369319
Drug: quetiapine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine (200 to 750 mg/day)
Study: 19369319
Drug: ziprasidone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone (40 to 160 mg/day)
Study: 15253956
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (Sustanon 100)
Study: 11849859
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg/day, n = 82)
Study: 11849859
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg/day, n = 83)
Study: 9688105
Drug: Sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10 mg once daily)
Study: 4574642
Drug: Paracetamol with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol with tepid sponging
Study: 21762493
Drug: Zhizhu pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhizhu pills containing immature orange fruit of Citrus aurantium L. (IFCA), 6 g each time, 3 times a day for 4 weeks
Study: 21762493
Drug: Zhizhu pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhizhu pills containing immature orange fruit of Citrus sinensis Osbeck (IFCS), 6 g each time, 3 times a day for 4 weeks
Study: 1502484
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg tablets three times daily for 4 weeks
Study: 6497518
Drug: Hydrochlorothiazide therapy
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide therapy (2 weeks)
Study: 6497518
Drug: Hydrochlorothiazide therapy
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide therapy (4 weeks)
Study: 28968031
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy + ozone therapy (subgroup 1a: intravenous ozonized physiological solution, n=28)
Study: 28968031
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy + ozone therapy (subgroup 1b: major ozonized autohemotherapy, n=29)
Study: 28968031
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment including gravitational therapy + medical ozone (subgroup 2a: standard medical therapy + ozonized physiological solution + gravitational therapy, n=31)
Study: 28968031
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment including gravitational therapy + medical ozone (subgroup 2b: standard medical therapy + major ozonized autohemotherapy + gravitational therapy, n=31)
Study: 28968031
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical therapy only (control group, n=20)
Study: 26269002
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg or 30 mg)
Study: 17264187
Drug: Sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10 mg)
Study: 19855170
Drug: HPV 6/11/16/18
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV 6/11/16/18 vaccine
Study: 16267842
Drug: Bromocriptine 25
Normalized name: bromocriptine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine 25 mg/day
Study: 14720615
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg drospirenone/30 microg ethinylestradiol
Study: 10866253
Drug: Bone Injection
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone Injection Gun
Study: 4045435
Drug: 5-micrograms recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-micrograms recombinant hepatitis B vaccine
Study: 4045435
Drug: 10-micrograms recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-micrograms recombinant hepatitis B vaccine
Study: 4045435
Drug: plasma-derived hepatitis
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: plasma-derived hepatitis B vaccine (5-micrograms)
Study: 4045435
Drug: plasma-derived hepatitis
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: plasma-derived hepatitis B vaccine (10-micrograms)
Study: 2956867
Drug: Intravenous enoximone
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoximone at a maximum cumulative dose of 3.0 mg/kg
Study: 2956867
Drug: Intravenous enoximone
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoximone at a maximum cumulative dose of 10.5 mg/kg
Study: 2956867
Drug: Intravenous enoximone
Normalized name: enoximone
DrugBank: Enoximone (DB04880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enoximone
Study: 2956867
Drug: Adverse effects
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse effects of intravenous enoximone
Study: 25427521
Drug: Individualized homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homeopathic treatment
Study: 23174090
Drug: D-cycloserine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine (1000 mg/d)
Study: 16649875
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of abstinence-based vouchers and cognitive-behavioral therapy
Study: 10819856
Drug: Atosiban (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atosiban (30 microg/min continuous subcutaneous infusion)
Study: 6437467
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg SSHA
Study: 6437467
Drug: 37.5 mg
Normalized name: pemoline 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg SSHA
Study: 6437467
Drug: 5000 units
Normalized name: A-25, 25000 units oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 units sodium heparin
Study: 30178515
Drug: Genotype-guided tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Genotype-guided tacrolimus dosing
Study: 30178515
Drug: Standard tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tacrolimus dosing
Study: 27553581
Drug: Landiolol infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Landiolol infusion (5 μg/kg/min during general anesthesia)
Study: 19921354
Drug: Landiolol infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Landiolol infusion
Study: 24554512
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill (OC) containing ethynyloestradiol and cyproterone acetate (EE‐CPA) for 4 months
Study: 24554512
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) 850 mg bid for 4 months
Study: 24554512
Drug: Metformin (MET)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (MET) or EE‐CPA for 4 months
Study: 15321222
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L Ringer's solution preload administered over 10 min before spinal anaesthesia
Study: 15321222
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received prophylactic infusion of ephedrine (60 mg in Ringer's solution 1000 ml) after spinal anaesthesia
Study: 7923256
Drug: 2 mg/day
Normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/day terazosin
Study: 7923256
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day terazosin
Study: 7923256
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day terazosin
Study: 3136963
Drug: Indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 25 mg three times daily for the first six postoperative weeks
Study: 25227499
Drug: Bevacizumab 1.25
Normalized name: Bevacizumab 1.25mg/0.05mL Intraocular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 1.25 mg
Study: 26445075
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment regimen
Study: 26445075
Drug: Discontinuous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuous treatment regimen
Study: 22464973
Drug: JNJ-37822681 10
Normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-37822681 10 mg bid
Study: 22464973
Drug: JNJ-37822681 20
Normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-37822681 20 mg bid
Study: 22464973
Drug: JNJ-37822681 30
Normalized name: JNJ-37822681
DrugBank: JNJ-37822681 (DB12579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-37822681 30 mg bid
Study: 21296118
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal and meningococcal serogroup C conjugate vaccine (9vPnC‐MnCC)
Study: 21296118
Drug: 9-valent pneumococcal
Normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-valent pneumococcal conjugate vaccine (9vPnC)
Study: 19293355
Drug: Beraprost sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beraprost sodium, 120 microg daily for 8 weeks
Study: 15153174
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lansoprazole orally disintegrating tablet dispersed in water and administered orally via syringe
Study: 15153174
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg intact lansoprazole orally disintegrating tablet administered directly onto the tongue without water
Study: 11557646
Drug: leflunomide 20
Normalized name: leflunomide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: leflunomide 20 mg/day
Study: 11557646
Drug: sulfasalazine 2
Normalized name: SULFASALAZINE 250MG/5ML SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfasalazine 2 g/day
Study: 7835329
Drug: Breakfast cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast cereal with 43 g sucrose
Study: 7835329
Drug: Breakfast cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast cereal with 0 g sucrose (non-sweetened)
Study: 29797909
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Feishu (BL 13), Xinshu (BL 15), Pishu (BL 20), Ganshu (BL 18), Shenshu (BL 23), Geshu (BL 17), and Shenmen (HT 7) once a day, with a 2-day interval after every 5 days of treatment for 3 weeks.
Study: 29797909
Drug: Alprazolam (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.4 mg or 0.8 mg) orally before sleep for 3 weeks.
Study: 23506383
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test, HbA1c, biochemical and anthropometric data
Study: 21685640
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Based Exposure Therapy (VRBET)
Study: 21685640
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Based Exposure Therapy (VRBET) combined with cognitive therapy
Study: 15612966
Drug: Budesonide once
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide once daily (up to 800 microg per day)
Study: 15612966
Drug: Budesonide twice
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide twice daily (up to 800 microg per day)
Study: 7717370
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose 13‐Cis‐Retinoic Acid (80 mg daily for 6 months)
Study: 7717370
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose 13‐Cis‐Retinoic Acid (200 mg po daily for 3 months)
Study: 7717370
Drug: Danazol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (800 mg po daily for 3 months)
Study: 2235346
Drug: L-cysteine (L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-cysteine (L group)
Study: 631413
Drug: Chlormethiazole syrup
Normalized name: chlormethiazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormethiazole syrup
Study: 31869281
Drug: Individually randomized
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually randomized group treatment trial
Study: 26482865
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 × 500 mg/day) and E (400 IU/day)
Study: 28991404
Drug: Inactivated trivalent
Normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated trivalent influenza vaccine (TIV)
Study: 22180452
Drug: Prednisone 25
Normalized name: prednisone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 25 mg
Study: 3871188
Drug: Prednisone 60
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 60 mg
Study: 22180452
Drug: Prednisone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (all doses)
Study: 19566585
Drug: SLIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLIT with a glycerinated mixture of birch, hazel and alder with a cumulative weekly dose of 24,000 SQ-U
Study: 19566585
Drug: SLIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLIT with a glycerinated mixture of birch, hazel and alder with a cumulative weekly dose of 200,000 SQ-U
Study: 16253583
Drug: Both atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both atorvastatin and pravastatin
Study: 10572352
Drug: Fluoxetine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine for six months
Study: 8951782
Drug: Aggressive cytoreductive
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive cytoreductive treatments with chemotherapeutic agents
Study: 8951782
Drug: Phlebotomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy and preventive antiplatelet therapy
Study: 1829574
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of alteplase (70 mg or 80 mg if body weight >= 90 kg)
Study: 6667627
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg slow-release salbutamol tablet
Study: 6667627
Drug: 1 standard
Normalized name: Kroger Universal 1 Standard Lancet 21G
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 standard 4 mg tablet
Study: 6667627
Drug: 2 standard
Normalized name: Onguard2 Standard 20 mm Vial Adaptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 standard 4 mg tablets
Study: 31752952
Drug: Inspiratory flow
Normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory flow of 400, 800, and 1200 ml/s
Study: 16940738
Drug: Intramuscular syntometrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular syntometrine
Study: 19603316
Drug: Intravenous syntocinon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous syntocinon
Study: 15041401
Drug: EC-MPS, 720
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-MPS, 720 mg b.i.d.
Study: 15041401
Drug: MMF, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF, 1000 mg b.i.d.
Study: 11583477
Drug: Thalidomide at
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide at a dose of 200 mg daily for 4 weeks
Study: 10933340
Drug: Flunitrazepam (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (2, 4 and 8 mg/70 kg)
Study: 10933340
Drug: Triazolam (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.25, 0.5 and 1 mg/70 kg)